Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Stocks found in the category TradersPro New Uptrend are low priced stocks priced between .20 and $7, with at least 50k shares of average shares trading per day. The stocks are starting new uptrends and have buy signals. These are high reward to risk stocks with the potential for very sharp moves. A stop should be maintained at the low of the most recent hold signal day. Target prices for exits can be determined by using the next level of resistance higher or by using Fibonacci resistance levels found using TradersPro. Trailing stops or letting the stock run until the next sell signal is also a sell strategy.